Pituitary adenoma · line 1 · Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SSA-refractory disease)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-SSA-ACROMEGALY |
| ID | IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PITUITARY-ADENOMA |
| Sources | SRC-NCCN-CNS-2025 SRC-NCCN-NET-2025 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode-exempted, safe to merge as draft content, not published/verified clinical advice). One of four parallel, cohort-specific 1L Indications for DIS-PITUITARY-ADENOMA, routed by ALGO-PITUITARY-ADENOMA-1L on the adenoma_hormone_type finding. Pegvisomant referenced via concurrent_therapy (add-on-to or switch-from ongoing SSA), not as a separate Indication, since it is not a distinct line of therapy within this cohort.
Used By
Algorithms
ALGO-PITUITARY-ADENOMA-1L- ALGO-PITUITARY-ADENOMA-1L
Disease
DIS-PITUITARY-ADENOMA- Pituitary adenoma